Health-Related Quality of Life Among Older Adult Related Hematopoietic Stem Cells (HSC) Donors (>60 yrs.) Is Equivalent to or Better Than That of Younger Adult Related Donors (18-60 yrs.)  by Switzer, Galen E. et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S47University of British Columbia j Child and Family Research
Institute, Vancouver, BC, Canada
Mixed hematopoietic chimerism is a promising approach to
achieving transplantation tolerance. Transient mixed hemato-
poietic chimerism leads to renal allograft tolerance inabout70%
of cynomolgus monkeys when the kidney is co-transplanted
with MHC-mismatched bone marrow (BMT). This same
approach failed to achieve tolerance with more immunogenic
organs such as lungs and hearts. Murine studies have demon-
strated that the addition of regulatory T cells (Tregs) to BMTs
using a non-myeloablative protocol (that is insufﬁcient to allow
engraftment), permits lasting mixed chimerism, BM engraft-
ment and skin graft tolerance. We aim to extend this approach
into the pre-clinical cynomolgus monkey model.
We have developed a protocol for the expansion of (100
million-1 billion) host polyclonal cynomolgusmacaque Tregs
(pTregs) (CD4+, CD25hi, CD127-/lo, FoxP3+). Cryopreserved
Tregs are thawed andwashed prior to infusion on days 0, 2, 5,
7 and (+/-) 50 to recipients conditioned with total body
irradiation (1.25-1.5cGy) on days -6 and -5, thymic irradia-
tion (7Gy) on day -1, ATGAM on days -2, -1 and 0, anti-CD40L
on days 0, 2, 5, 7, 9 and 12 and cyclosporine or rapamycin
(monotherapy) for 30 days (from day -2 to day 28 after BMT).
To assess for tolerance, a skin or kidney allograft from the
same donor was grafted four months post-BMT, after
discontinuation of all immunosuppression.
Control animals (which did not receive Tregs (n¼4) lost
chimerism within 40 days. In vitro, anti-donor proliferative
responses were observed, and donor kidneys were rejected.
In contrast, animals that received Tregs together with BMT (n
¼ 2) developed remarkably high and long-lasting chimerism,
with a peak of>90% inmyeloid lineages and range of 110-335
days. Unfortunately, experimental animals that reactivated
CMV early after BMTeither succumbed to CMV viremia or lost
the BM graft when treated with myelotoxic antivirals. The
substitution of rapamycin for CyA allowed control of early
CMV reactivation (n¼3 animals) and boosted the number of
Tregs in the peripheral blood. T cell chimerism was observed
only in Treg recipients, with high CD31 expression, suggest-
ing new thymic emigrants. Tregs animals were donor-hypo-
responsive 7 weeks post-BMT. One animal received a kidney
graft on day +120 which was accepted without immuno-
suppression until euthanasia on day 335 (without evidence
for histopathological rejection and with normal kidney
function). The second Treg recipient received skin grafts on
day 119. The third party graft is suspected to be rejected
(histopathology to be conﬁrmed)within 7 days and the donor
skin is visually healthy three weeks post-transplant.
In summary, host pTregs given at the time of BMT across
MHC barriers prolongs donor chimerism up to 335 days
(extending it beyond 60 days for the ﬁrst time in 20 years
using this protocol) without GVHD and allows for the sur-
vival of donor organs transplanted four months post-BMT.Figure 1. Longitudinal physical and mental health status of older and younger
adult related PBSC donors.27
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It is critical to understand HRQoL among older related sib-
lings who are increasingly asked to donate HSC. Findings
presented here are from a 5 year study of related donor (RD)
safety and HRQoL (RDSafe). The goal was to compare HRQoL
in older vs. younger adult RD.
Participants were older adult RD (ages >60 yrs; median¼65
yrs; n¼105) and younger adult RD (ages 18-60; median¼42
yrs; n¼59) who donated PBSC at domestic U.S. centers be-
tween 3/2010 and 4/2013. Data were collected via structured
telephone interviews at pre-donation, and 4 weeks and 1 year
post-donation. Interviews focused on socio-demographics,
physical and mental health, and donation-related perceptions
using well-validated instruments including the SF-12v2 to
assess general physical/mental health. Odds ratios for dichot-
omous variables t-tests for continuous variables and mixed
linear models were used to examine age group differences.
Demographics: Older RDwere less likely to be employed, and
more likely be white, married, and to have children. Pre-
donation: Pre-donation, older RD had poorer physical health
(t¼-3.28; p<.01) but did not differ from younger RD on psy-
chosocial variables including general mental health, depres-
sion, and anxiety. There were no group differences in
ambivalence, satisfaction, or medical concerns about donation
although older RD were more likely to consult their physician
about donation (OR¼13.18; p<.001). Older RD had fewer
work/family concerns (t¼-2.04; p<.05). Post-donation: 4
weeks post-donation, there were no group differences in
general physical health, mental health, or any of 12 donation-
related symptoms. Older RD were less likely to report dona-
tion-related pain (t¼-2.29; p<.05) and continued to have
fewer work/family concerns about the donation process
(t¼-3.39; p<.01). At 1 year post-donation, there were no dif-
ferences in general physical and mental health or in the
percent of RD reporting feeling completely back to normal.
There was a nonsigniﬁcant trend for older RD to report a
longer recovery period (t¼1.78; p¼.08). Older RD reported
fewer current problems sleeping (OR¼0.39; p<.05) but did not
differ from younger RD on any other symptoms or in concern
about longer-term donation effects. Mixed linear models
(Figure 1) indicated that older RD had poorer physical health
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no main effect difference by data collection time point and no
age by time interaction for physical or mental health.
Despite having somewhat poorer overall general pre-dona-
tion health, older RD experience similar e and in some do-
mains betteredonation-related HRQoL compared to younger
RD. This is a reassuring ﬁnding that supports the use of older
family members as donors and will further inform the
counseling and consent of older RD.28
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Introduction: Allogeneic hematopoietic cell trans-
plantation is effective in patients (pts) with high-riskTable
Characteristic, N ¼ 27 n (%) unless stated
Male gender 16 (59)
Age at dUCBT, median (range) 29 (17-61)
Prior autologous transplant 25 (92.5)
Response prior to dUCBT
Complete Remission 6 (22.2)
Partial Remission 9 (33.3)
Stable Disease 5 (18.5)
Progressive Disease 7 (26)
Conditioning Regimen
Fludarabine/low-dose cyclophosphamide/
TBI 2Gy +/- ATG
10 (37)
Fludarabine/Clofarabine/Busulfan/ATG/
TBI 2 Gy
3 (11)
Fludarabine/Melphalan/ATG 2 (7.5)
Melphalan/Thiotepa/Fludarabine/ATG 12 (44.5)
Total Nucleated Cell Dose (x108/kg) 0.44 (range 0.12-5.94)
HLA match
4/6, 4/6 15 (55.6)
4/6, 5/6 6 (22.2)
5/6, 5/6 5 (18.5)
6/6, 6/6 1 (3.7)
Figure. Left: PFS and overall survival for all patients. Right: Overall survival aclymphoid malignancies including Hodgkin lymphoma (HL).
We studied 27 pts who received double umbilical cord
blood transplant (dUCBT) at The UT M.D. Anderson Cancer
Center or The Royal Melbourne Hospital, Australia for
relapsed/refractory HL.
Patients and Methods: Median number of prior treatments
was 4 (range 2-6); 25 of 27 had had prior autologous trans-
plant. 45% did not achieve at least partial response to their
most recent prior therapy and 26% had progressive disease.
Pts were treated consecutively between Aug 2003 and May
2014. All pts received dUCBT from4/6-6/6matched cord blood
units. Graft versus host disease (GVHD) prophylaxis was
tacrolimus or cyclosporine plus low dose methotrexate or
mycophenolate mofetil. Pts were treated on ex vivo expansion
studies using liquid culture media (N¼8), mesenchymal
stromal cells (N¼3) or fucosylation (N¼3) as available.
Results: Pt and transplant characteristics are described in
Table 1. All pts engrafted. Median time to neutrophil recovery
(ANC> 500/mm3) was 17 days (range: 5-38). Median follow-
up after transplant was 14 months. Cumulative incidences of
grade II acute GVHD and extensive chronic GVHDwere 33.5%
(95% CI 18.8-52.4) and 40.5% (24.7-59.6), respectively. No pt
developed grade III-IV acute GVHD. Sixteen of 27 pts
achieved complete remission (CR) after alloHCT; 7 had
progressive disease at a median time of 7.4 months post-
transplant (range 4.1-36.0). At the time of last follow up 16
of 27 pts were alive. Relapse contributed to death in 3 pts.
The 5-year cumulative incidence of non-relapse mortality
(NRM) was 37.9% (95% CI: 20.9-59.0). Five year probabilities
of progression free-survival (PFS), and overall survival (OS)
were 31.3 (95% CI: 15.0-54.0) and 47.9 (95% CI: 26.2-70.5),
respectively (Figure). Small numbers limited the ability to
deﬁne prognostic factors; however there was a trend
toward inferior survival in pts achieving less than PR to
their most recent prior treatment (p¼0.12).
Conclusions: dUCBT is effective for patients with advanced
HL. Relapse rate was low and approximately 30% of pts
achieve long-term disease-free survival, including pts with
chemorefractory disease prior to dUCBT.29
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